Caris Life Sciences Inc – Current Financial and Market Overview
Company profile
Caris Life Sciences Inc. is listed on Nasdaq and operates in the health‑care sector as an artificial‑intelligence and precision‑medicine company. The firm develops and commercialises solutions that use comprehensive molecular data and machine‑learning algorithms to support clinical decision‑making for patients worldwide.
Recent financial data
| Item | Value |
|---|---|
| Closing price (2025‑10‑29) | USD 31.17 |
| 52‑week high | USD 42.50 |
| 52‑week low | USD 25.40 |
| Market capitalization | USD 8.28 billion |
| Price‑to‑earnings ratio | –1.97 (negative) |
News environment
There are no publicly released statements, earnings reports, board meeting outcomes, investor presentations, press releases, or dividend announcements that relate specifically to Caris Life Sciences Inc. on the dates provided (31 October 2025 and 30 October 2025). All news items supplied refer to other listed companies such as Regency Fincorp Limited, Bank of Baroda, and Shriram Finance Limited.
Conclusion
The available data indicate that Caris Life Sciences continues to trade within the range of its 52‑week high and low, with a market cap of over USD 8 billion. No new corporate actions or financial results have been disclosed for the quarter or half‑year ended 30 September 2025, so no updates are available beyond the existing market metrics.